Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Sold by Leeward Investments LLC MA

Leeward Investments LLC MA decreased its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 0.3% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 404,728 shares of the company’s stock after selling 1,365 shares during the quarter. Prestige Consumer Healthcare accounts for about 1.4% of Leeward Investments LLC MA’s holdings, making the stock its 13th biggest holding. Leeward Investments LLC MA’s holdings in Prestige Consumer Healthcare were worth $29,181,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Opal Wealth Advisors LLC acquired a new stake in Prestige Consumer Healthcare in the second quarter worth about $26,000. Quest Partners LLC lifted its holdings in Prestige Consumer Healthcare by 2,826.7% in the second quarter. Quest Partners LLC now owns 439 shares of the company’s stock worth $30,000 after purchasing an additional 424 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in Prestige Consumer Healthcare by 80.6% in the first quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company’s stock worth $33,000 after purchasing an additional 208 shares during the period. Northwestern Mutual Wealth Management Co. lifted its holdings in Prestige Consumer Healthcare by 562.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock worth $35,000 after purchasing an additional 433 shares during the period. Finally, Gladius Capital Management LP acquired a new stake in Prestige Consumer Healthcare in the second quarter worth about $35,000. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare Stock Performance

Shares of Prestige Consumer Healthcare stock opened at $77.44 on Thursday. Prestige Consumer Healthcare Inc. has a 12 month low of $56.61 and a 12 month high of $79.25. The company has a quick ratio of 1.90, a current ratio of 3.23 and a debt-to-equity ratio of 0.65. The stock has a market cap of $3.84 billion, a PE ratio of 18.93, a price-to-earnings-growth ratio of 2.08 and a beta of 0.47. The business has a fifty day simple moving average of $72.31 and a 200-day simple moving average of $69.71.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.90 earnings per share for the quarter, topping analysts’ consensus estimates of $0.86 by $0.04. The business had revenue of $267.10 million for the quarter, compared to the consensus estimate of $260.54 million. Prestige Consumer Healthcare had a net margin of 18.43% and a return on equity of 12.55%. Prestige Consumer Healthcare’s revenue for the quarter was down 4.4% compared to the same quarter last year. During the same period in the prior year, the business posted $1.06 earnings per share. On average, sell-side analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on PBH. DA Davidson upped their price target on shares of Prestige Consumer Healthcare from $93.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, August 28th. Jefferies Financial Group reissued a “hold” rating and issued a $76.00 price target (up from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $94.20.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.